IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD

NCT07484113 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

cGVHD

Interventions

DRUG: Belumosudil
DRUG: Sarilumab

Sponsor

Stanford University